Onier N, Hilpert S, Reveneau S, Arnould L, Saint-Giorgio V, Exbrayat J M, Jeannin J F
Laboratoire d'Immunologie et d'Immunothérapie des Cancers, Ecole Pratique des Hautes Etudes, INSERM U517, Université de Bourgogne, Dijon, France.
Int J Cancer. 1999 May 31;81(5):755-60. doi: 10.1002/(sici)1097-0215(19990531)81:5<755::aid-ijc15>3.0.co;2-3.
It is well documented that nitric oxide (NO) is an effector molecule of macrophage-mediated tumor cell toxicity in vitro; however, little is known about the role of NO in the antitumor immune response in vivo. We have developed a treatment protocol using lipid A. We have investigated the effects of lipid A on inducible NO synthase (NOS II) expression and evolution inside tumors during the course of treatment. Lipid A (OM-174) treatment induced tumor regression in rats bearing established colon tumors. Furthermore, NO was synthesized and secreted inside the tumors of lipid A-treated rats, as demonstrated by the increase of NOS II mRNA and NOS II content in the tumors, as well as of NOS II activity and NO production. During treatment, NOS II was localized in tumor cells only. Lipid A had no direct effect on tumor cells in vitro, while the combination of interferon gamma (IFN-gamma) plus interleukin-1 beta (IL-1beta) induced production of NO by tumor cells which was cytostatic. The content of IFN-gamma and IL-1beta in tumors was enhanced during lipid A treatment; this is in agreement with an indirect effect of lipid A in vivo via the IFN-gamma and IL-1beta pathways.
已有充分文献证明,一氧化氮(NO)是巨噬细胞介导的体外肿瘤细胞毒性的效应分子;然而,关于NO在体内抗肿瘤免疫反应中的作用却知之甚少。我们开发了一种使用脂多糖A的治疗方案。我们研究了脂多糖A在治疗过程中对肿瘤内诱导型一氧化氮合酶(NOS II)表达及演变的影响。脂多糖A(OM - 174)治疗可使患有既定结肠肿瘤的大鼠肿瘤消退。此外,如肿瘤中NOS II mRNA和NOS II含量的增加以及NOS II活性和NO生成的增加所示,脂多糖A治疗的大鼠肿瘤内合成并分泌了NO。在治疗期间,NOS II仅定位于肿瘤细胞中。脂多糖A在体外对肿瘤细胞无直接作用,而γ干扰素(IFN - γ)加白细胞介素 - 1β(IL - 1β)的组合可诱导肿瘤细胞产生具有细胞抑制作用的NO。在脂多糖A治疗期间,肿瘤中IFN - γ和IL - 1β的含量增加;这与脂多糖A通过IFN - γ和IL - 1β途径在体内产生的间接作用一致。